| Name | Title | Contact Details |
|---|
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.
International Oncology Network is a Frisco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market.
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.